Neuropsychopharmacology and the affective disorders.  (Third of three parts)
D000342:Affective Symptoms / Q000188:drug therapy* / Q000378:metabolism / Q000628:therapy; D000588:Amines / Q000378:metabolism; D000661:Amphetamine / Q000627:therapeutic use; D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism; D002395:Catecholamines / Q000378:metabolism; D003042:Cocaine / Q000627:therapeutic use; D003863:Depression / Q000378:metabolism; D004285:Dogs; D004298:Dopamine / Q000378:metabolism; D004565:Electroconvulsive Therapy; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D007211:Indoles / Q000378:metabolism; D008094:Lithium / Q000627:therapeutic use; D009638:Norepinephrine / Q000378:metabolism; D011600:Psychopharmacology; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D014363:Tryptamines / Q000652:urine
D000588:Amines; D000928:Antidepressive Agents; D002395:Catecholamines; D007211:Indoles; D014363:Tryptamines; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D008094:Lithium; D000661:Amphetamine; D003042:Cocaine; D004298:Dopamine; D009638:Norepinephrine